{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:01:54Z","timestamp":1792123314557,"version":"4.4.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Heart failure (HF) represents a significant global health challenge, characterized by high morbidity and mortality rates, decreased quality of life and a significant financial and economic burden. The prevalence of HF continues to rise, driven by an ageing population and an increasing burden of comorbidities such as hypertension, diabetes and obesity. Understanding the complex pathophysiology and developing effective treatments are critical for improving patient outcomes, yet the range of effective, life-prolonging medication classes has remained mostly constant in the last few decades. The introduction of angiotensin receptor neprilysin inhibitors (ARNI) was a major breakthrough in HF management, for the first time targeting the natriuretic peptide system in addition to the renin\u2013angiotensin\u2013aldosterone pathway to potentiate the effects of older drug classes. ARNI shows superiority in clinical outcomes compared to previous guideline-directed therapies, especially in patients with reduced ejection fraction (EF). It has now been implemented into international guidelines, endorsing its use in patients with HF and reduced ejection fraction (HFrEF) and HF with mildly reduced ejection fraction (HFmrEF). This review summarises the mechanism of action of Sac\/Val, presents key clinical trials in a range of patient populations and HF aetiologies and outlines gaps in knowledge and potential novel uses of Sac\/Val.<\/jats:p>","DOI":"10.1007\/s10741-024-10471-1","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T06:07:48Z","timestamp":1736230068000},"page":"387-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sacubitril\/valsartan in a wide spectrum of heart failure patients (from mechanisms of action to outcomes in specific populations)"],"prefix":"10.1007","volume":"30","author":[{"given":"Przemyslaw","family":"Rajzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"issue":"6","key":"10471_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMOA1812851\/SUPPL_FILE\/NEJMOA1812851_DATA-SHARING.PDF","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K et al (2019) Angiotensin-Neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539\u2013548. https:\/\/doi.org\/10.1056\/NEJMOA1812851\/SUPPL_FILE\/NEJMOA1812851_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"3","key":"10471_CR2","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/ehf2.14255","volume":"10","author":"AH Behnoush","year":"2023","unstructured":"Behnoush AH, Khalaji A, Naderi N, Ashraf H, von Haehling S (2023) ACC\/AHA\/HFSA 2022 and ESC 2021 guidelines on heart failure comparison. ESC Heart Fail 10(3):1531\u20131544. https:\/\/doi.org\/10.1002\/ehf2.14255","journal-title":"ESC Heart Fail"},{"key":"10471_CR3","doi-asserted-by":"publisher","unstructured":"Simmonds SJ, Cuijpers I, Heymans S, Jones EAV (2020) Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells 9(1). https:\/\/doi.org\/10.3390\/cells9010242","DOI":"10.3390\/cells9010242"},{"issue":"5","key":"10471_CR4","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/JAMA.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL (2020) Heart failure with reduced ejection fraction: a review. JAMA 324(5):488\u2013504. https:\/\/doi.org\/10.1001\/JAMA.2020.10262","journal-title":"JAMA"},{"issue":"10","key":"10471_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","volume":"44","author":"K Yamamoto","year":"2021","unstructured":"Yamamoto K, Rakugi H (2021) Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment. Hypertension Res 44(10):1239\u201350. https:\/\/doi.org\/10.1038\/s41440-021-00706-1","journal-title":"Hypertension Res"},{"issue":"10367","key":"10471_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400(10367):1938\u20131952. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1","journal-title":"Lancet"},{"issue":"6","key":"10471_CR7","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1002\/ehf2.14559","volume":"10","author":"U Kocaba\u015f","year":"2023","unstructured":"Kocaba\u015f U, Ergin I, K\u0131vrak T, Y\u0131lmaz \u00d6ztekin GM, Tan\u0131k VO, \u00d6zdemir \u0130 et al (2023) Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. ESC Heart Fail 10(6):3677\u20133689. https:\/\/doi.org\/10.1002\/ehf2.14559","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10471_CR8","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1002\/ehf2.14358","volume":"10","author":"X Chen","year":"2023","unstructured":"Chen X, Kang Y, Dahlstrom U, Fu M (2023) Impact of adherence to guideline-directed therapy on risk of death in HF patients across an ejection fraction spectrum. ESC Heart Fail 10(6):3656\u20133666. https:\/\/doi.org\/10.1002\/ehf2.14358","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10471_CR9","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/ehf2.14524","volume":"10","author":"R Matsukawa","year":"2023","unstructured":"Matsukawa R, Okahara A, Tokutome M, Itonaga J, Koga E, Hara A et al (2023) A scoring evaluation for the practical introduction of guideline-directed medical therapy in heart failure patients. ESC Heart Fail 10(6):3352\u20133363. https:\/\/doi.org\/10.1002\/ehf2.14524","journal-title":"ESC Heart Fail"},{"issue":"1","key":"10471_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/ehf2.14206","volume":"10","author":"KM Odegaard","year":"2023","unstructured":"Odegaard KM, Lirhus SS, Melberg HO, Hallen J, Halvorsen S (2023) Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014\u20132020. ESC Heart Fail 10(1):405\u2013415. https:\/\/doi.org\/10.1002\/ehf2.14206","journal-title":"ESC Heart Fail"},{"key":"10471_CR11","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2014) Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. New England J Med 371(11). https:\/\/doi.org\/10.1056\/NEJMoa1409077","DOI":"10.1056\/NEJMoa1409077"},{"issue":"12","key":"10471_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/J.JACC.2024.01.027","volume":"83","author":"DA Morrow","year":"2024","unstructured":"Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG et al (2024) Sacubitril\/Valsartan in patients hospitalized with decompensated heart failure. J Am Coll Cardiol 83(12):1123\u20131132. https:\/\/doi.org\/10.1016\/J.JACC.2024.01.027","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10471_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"issue":"19","key":"10471_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/JAMA.2021.18463","volume":"326","author":"B Pieske","year":"2021","unstructured":"Pieske B, Wachter R, Shah SJ, Baldridge A, Szeczoedy P, Ibram G et al (2021) Effect of Sacubitril\/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA 326(19):1919\u20131929. https:\/\/doi.org\/10.1001\/JAMA.2021.18463","journal-title":"JAMA"},{"issue":"20","key":"10471_CR15","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","volume":"385","author":"MA Pfeffer","year":"2021","unstructured":"Pfeffer MA, Claggett B, Lewis EF, Granger CB, K\u00f8ber L, Maggioni AP et al (2021) Angiotensin receptor\u2013neprilysin inhibition in acute myocardial infarction. N Engl J Med 385(20):1845\u20131855. https:\/\/doi.org\/10.1056\/NEJMoa2104508","journal-title":"N Engl J Med"},{"key":"10471_CR16","doi-asserted-by":"publisher","unstructured":"Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF et al (2022) The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial. Circulation 146(23). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060841","DOI":"10.1161\/CIRCULATIONAHA.122.060841"},{"issue":"1","key":"10471_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1001\/JAMACARDIO.2021.4567","volume":"7","author":"DL Mann","year":"2022","unstructured":"Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE et al (2022) Effect of treatment with Sacubitril\/Valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol 7(1):17\u201325. https:\/\/doi.org\/10.1001\/JAMACARDIO.2021.4567","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10471_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JACC.2023.04.019\/SUPPL_FILE\/MMC1.DOCX","volume":"82","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S et al (2023) Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol 82(1):1\u201312. https:\/\/doi.org\/10.1016\/J.JACC.2023.04.019\/SUPPL_FILE\/MMC1.DOCX","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10471_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/EJHF.1670","volume":"22","author":"M Senni","year":"2020","unstructured":"Senni M, Wachter R, Witte KK, Straburzynska-Migaj E, Belohlavek J, Fonseca C et al (2020) Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail 22(2):303\u2013312. https:\/\/doi.org\/10.1002\/EJHF.1670","journal-title":"Eur J Heart Fail"},{"key":"10471_CR20","doi-asserted-by":"publisher","unstructured":"Niu CY, Yang SF, Ou SM, Wu CH, Huang PH, Hung CL et al (2022) Sacubitril\/Valsartan in patients with heart failure and concomitant end-stage kidney disease. J Am Heart Assoc 11(18). https:\/\/doi.org\/10.1161\/JAHA.122.026407","DOI":"10.1161\/JAHA.122.026407"},{"key":"10471_CR21","doi-asserted-by":"publisher","unstructured":"Yang X, Jin J, Cheng M, Xu J, Bai Y (2024) The role of sacubitril\/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis. Renal Fail 46(1). https:\/\/doi.org\/10.1080\/0886022X.2024.2349135","DOI":"10.1080\/0886022X.2024.2349135"},{"issue":"1","key":"10471_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.114.012284","volume":"131","author":"SL Kristensen","year":"2015","unstructured":"Kristensen SL, K\u00f8ber L, Jhund PS, Solomon SD, Kjekshus J, McKelvie RS et al (2015) International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. Circulation 131(1):43\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.012284","journal-title":"Circulation"},{"key":"10471_CR23","doi-asserted-by":"publisher","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR et al (2017) Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5(5). https:\/\/doi.org\/10.1016\/S2213-8587(17)30087-6","DOI":"10.1016\/S2213-8587(17)30087-6"},{"issue":"1","key":"10471_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/EHF2.14166","volume":"10","author":"KK Witte","year":"2023","unstructured":"Witte KK, Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Fonseca C et al (2023) Influence of diabetes on sacubitril\/valsartan titration and clinical outcomes in patients hospitalized for heart failure. ESC Heart Fail 10(1):80\u201389. https:\/\/doi.org\/10.1002\/EHF2.14166","journal-title":"ESC Heart Fail"},{"key":"10471_CR25","doi-asserted-by":"publisher","unstructured":"Varghese TPBT (2024) Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). Curr Problems Cardiol 49(4). https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102411","DOI":"10.1016\/j.cpcardiol.2024.102411"},{"key":"10471_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2021.10.149","volume":"345","author":"J Biegus","year":"2021","unstructured":"Biegus J, Nawrocka-Millward S, Zymlinski R, Fudim M, Testani J, Marciniak D et al (2021) Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. Int J Cardiol 345:54\u201360. https:\/\/doi.org\/10.1016\/j.ijcard.2021.10.149","journal-title":"Int J Cardiol"},{"issue":"5","key":"10471_CR27","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/J.1527-5299.2000.01156.X","volume":"8","author":"RC Peterson","year":"2002","unstructured":"Peterson RC, Dunlap ME (2002) Angiotensin II receptor blockers in the treatment of heart failure. Congest Heart Fail 8(5):246\u2013256. https:\/\/doi.org\/10.1111\/J.1527-5299.2000.01156.X","journal-title":"Congest Heart Fail"},{"key":"10471_CR28","doi-asserted-by":"publisher","first-page":"678886","DOI":"10.3389\/FPHAR.2021.678886\/BIBTEX","volume":"12","author":"JJ Xu","year":"2021","unstructured":"Xu JJ, Li RJ, Zhang ZH, Yang C, Liu SX, Li YL et al (2021) Loganin inhibits angiotensin II\u2013induced cardiac hypertrophy through the JAK2\/STAT3 and NF-\u03baB signaling pathways. Front Pharmacol 12:678886. https:\/\/doi.org\/10.3389\/FPHAR.2021.678886\/BIBTEX","journal-title":"Front Pharmacol"},{"issue":"2","key":"10471_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1161\/HYPERTENSIONAHA.107.101717","volume":"51","author":"L Gao","year":"2008","unstructured":"Gao L, Wang W, Wang W, Li H, Sumners C, Zucker IH (2008) Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats. Hypertension (Dallas, Tex: 1979) 51(2):521\u20137. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.101717","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"issue":"1","key":"10471_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/S10741-019-09855-5","volume":"25","author":"NR Pugliese","year":"2019","unstructured":"Pugliese NR, Masi S, Taddei S (2019) The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev 25(1):31\u201342. https:\/\/doi.org\/10.1007\/S10741-019-09855-5","journal-title":"Heart Fail Rev"},{"key":"10471_CR31","doi-asserted-by":"publisher","unstructured":"Zucker IH, Xiao L, Haack KK (2014) The central RAS and sympathetic nerve activity in chronic heart failure. Clin Sci (London, England: 1979) 126(10). https:\/\/doi.org\/10.1042\/CS20130294","DOI":"10.1042\/CS20130294"},{"issue":"11","key":"10471_CR32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","volume":"17","author":"JP Goetze","year":"2020","unstructured":"Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ (2020) Cardiac natriuretic peptides. Nat Rev Cardiol 17(11):698\u2013717. https:\/\/doi.org\/10.1038\/s41569-020-0381-0","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"10471_CR33","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1161\/JAHA.115.002423","volume":"4","author":"R Kerkel\u00e4","year":"2015","unstructured":"Kerkel\u00e4 R, Ulvila J, Magga J (2015) Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J Am Heart Assoc 4(10):2423. https:\/\/doi.org\/10.1161\/JAHA.115.002423","journal-title":"J Am Heart Assoc"},{"key":"10471_CR34","doi-asserted-by":"publisher","unstructured":"R\u00f8rth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS et al (2020) Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction. Circulation: Heart Fail 13(2). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006541","DOI":"10.1161\/CIRCHEARTFAILURE.119.006541"},{"issue":"1","key":"10471_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.15420\/CFR.2016:1:1","volume":"2","author":"JT Menendez","year":"2016","unstructured":"Menendez JT (2016) The mechanism of action of LCZ696. Cardiac Fail Rev 2(1):40. https:\/\/doi.org\/10.15420\/CFR.2016:1:1","journal-title":"Cardiac Fail Rev"},{"issue":"4","key":"10471_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1161\/01.RES.0000117070.86556.9F","volume":"94","author":"AM Kapoun","year":"2004","unstructured":"Kapoun AM, Liang F, O\u2019Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA (2004) B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-\u03b2 in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circulation Res 94(4):453\u201361. https:\/\/doi.org\/10.1161\/01.RES.0000117070.86556.9F","journal-title":"Circulation Res"},{"issue":"5","key":"10471_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","volume":"25","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J et al (2023) Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the heart failure association of the european society of cardiology, heart failure society of America and Japanese heart failure society. Eur J Heart Fail 25(5):616\u2013631. https:\/\/doi.org\/10.1002\/ejhf.2848","journal-title":"Eur J Heart Fail"},{"key":"10471_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijcard.2018.04.045","volume":"281","author":"M Volpe","year":"2019","unstructured":"Volpe M, Battistoni A, Rubattu S (2019) Natriuretic peptides in heart failure: current achievements and future perspectives. Int J Cardiol 281:186\u2013189. https:\/\/doi.org\/10.1016\/j.ijcard.2018.04.045","journal-title":"Int J Cardiol"},{"issue":"1","key":"10471_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/J.JACBTS.2022.05.010","volume":"8","author":"B Bozkurt","year":"2023","unstructured":"Bozkurt B, Nair AP, Misra A, Scott CZ, Mahar JH, Fedson S (2023) Neprilysin inhibitors in heart\u00a0failure: the science, mechanism of action, clinical studies, and unanswered questions. JACC: Basic Transl Sci 8(1):88\u2013105. https:\/\/doi.org\/10.1016\/J.JACBTS.2022.05.010","journal-title":"JACC: Basic Transl Sci"},{"key":"10471_CR40","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/J.NPEP.2015.12.005","volume":"58","author":"E Mistrova","year":"2016","unstructured":"Mistrova E, Kruzliak P, Chottova DM (2016) Role of substance P in the cardiovascular system. Neuropeptides 58:41\u201351. https:\/\/doi.org\/10.1016\/J.NPEP.2015.12.005","journal-title":"Neuropeptides"},{"issue":"23","key":"10471_CR41","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1161\/01.CIR.100.23.2305","volume":"100","author":"LJ Dell'Italia","year":"1999","unstructured":"Dell\u2019Italia LJ, Oparil S (1999) Bradykinin in the heart. Circulation 100(23):2305\u20132307. https:\/\/doi.org\/10.1161\/01.CIR.100.23.2305","journal-title":"Circulation"},{"key":"10471_CR42","doi-asserted-by":"publisher","unstructured":"Cui N, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Tanaka M et al (2021) Adrenomedullin-RAMP2 and -RAMP3 systems regulate cardiac homeostasis during cardiovascular stress. Endocrinology 162(3). https:\/\/doi.org\/10.1210\/endocr\/bqab001","DOI":"10.1210\/endocr\/bqab001"},{"issue":"2","key":"10471_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.0306-5251.2001.01428.x","volume":"52","author":"MC Petrie","year":"2001","unstructured":"Petrie MC, McDonald JE, Hillier C, Morton JJ, McMurray JJ (2001) Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans. Brit J Clinical Pharma 52(2):165\u2013168. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01428.x","journal-title":"Brit J Clinical Pharma"},{"issue":"6","key":"10471_CR44","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1210\/ENDO.136.6.7750467","volume":"136","author":"TC Murphy","year":"1995","unstructured":"Murphy TC, Samson WK (1995) The novel vasoactive hormone, adrenomedullin, inhibits water drinking in the rat. Endocrinology 136(6):2459\u20132463. https:\/\/doi.org\/10.1210\/ENDO.136.6.7750467","journal-title":"Endocrinology"},{"issue":"2","key":"10471_CR45","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1210\/ENDO.138.2.4943","volume":"138","author":"WK Samson","year":"1997","unstructured":"Samson WK, Murphy TC (1997) Adrenomedullin inhibits salt appetite. Endocrinology 138(2):613\u2013616. https:\/\/doi.org\/10.1210\/ENDO.138.2.4943","journal-title":"Endocrinology"},{"issue":"1\u20133","key":"10471_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0167-0115(03)00021-1","volume":"112","author":"CJ Charles","year":"2003","unstructured":"Charles CJ, Lainchbury JG, Nicholls MG, Rademaker MT, Richards AM, Troughton RW (2003) Adrenomedullin and the renin\u2013angiotensin\u2013aldosterone system. Regul Pept 112(1\u20133):41\u201349. https:\/\/doi.org\/10.1016\/S0167-0115(03)00021-1","journal-title":"Regul Pept"},{"issue":"4","key":"10471_CR47","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/hr.2010.8","volume":"33","author":"T Kita","year":"2010","unstructured":"Kita T, Tokashiki M, Kitamura K (2010) Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. Hypertens Res 33(4):374\u20139. https:\/\/doi.org\/10.1038\/hr.2010.8","journal-title":"Hypertens Res"},{"issue":"6","key":"10471_CR48","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/EJHF.1437","volume":"21","author":"JM ter Maaten","year":"2019","unstructured":"ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD et al (2019) Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail 21(6):732\u2013743. https:\/\/doi.org\/10.1002\/EJHF.1437","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10471_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMOA1100171\/SUPPL_FILE\/NEJMOA1100171_DISCLOSURES.PDF","volume":"365","author":"CM O'Connor","year":"2011","unstructured":"O\u2019Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365(1):32\u201343. https:\/\/doi.org\/10.1056\/NEJMOA1100171\/SUPPL_FILE\/NEJMOA1100171_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"10471_CR50","doi-asserted-by":"publisher","first-page":"650124","DOI":"10.3389\/FPHYS.2021.650124\/BIBTEX","volume":"12","author":"O Gidl\u00f6f","year":"2021","unstructured":"Gidl\u00f6f O (2021) Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure. Front Physiol 12:650124. https:\/\/doi.org\/10.3389\/FPHYS.2021.650124\/BIBTEX","journal-title":"Front Physiol"},{"issue":"2","key":"10471_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0735-1097(00)00741-5","volume":"36","author":"DR McClean","year":"2000","unstructured":"McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG (2000) The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol 36(2):479\u2013486. https:\/\/doi.org\/10.1016\/S0735-1097(00)00741-5","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10471_CR52","first-page":"330","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L (2015) Entresto (Sacubitril\/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits 8(6):330","journal-title":"Am Health Drug Benefits"},{"issue":"suppl_J","key":"10471_CR53","doi-asserted-by":"publisher","first-page":"J10","DOI":"10.1093\/EURHEARTJ\/SUI057","volume":"7","author":"JJV McMurray","year":"2005","unstructured":"McMurray JJV (2005) The role of angiotensin II receptor blockers in the management of heart failure. European Heart J Suppl 7(suppl_J):J10\u2013J4. https:\/\/doi.org\/10.1093\/EURHEARTJ\/SUI057","journal-title":"European Heart J Suppl"},{"issue":"6","key":"10471_CR54","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1002\/ehf2.13064","volume":"7","author":"R Zymlinski","year":"2020","unstructured":"Zymlinski R, Sierpinski R, Metra M, Cotter G, Sokolski M, Siwolowski P et al (2020) Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. ESC Heart Fail 7(6):3536\u20133544. https:\/\/doi.org\/10.1002\/ehf2.13064","journal-title":"ESC Heart Fail"},{"key":"10471_CR55","doi-asserted-by":"publisher","first-page":"1102521","DOI":"10.3389\/FCVM.2023.1102521\/BIBTEX","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Zou Y, Li Y, Wang H, Sun W, Liu B (2023) The history and mystery of sacubitril\/valsartan: from clinical trial to the real world. Front Cardiovasc Med 10:1102521. https:\/\/doi.org\/10.3389\/FCVM.2023.1102521\/BIBTEX","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10471_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/00005344-199704000-00017","volume":"29","author":"T Tagawa","year":"1997","unstructured":"Tagawa T, Mohri M, Tagawa H, Egashira K, Shimokawa H, Kuga T et al (1997) Role of nitric oxide in substance P-induced vasodilation differs between the coronary and forearm circulation in humans. J Cardiovasc Pharmacol 29(4):546\u2013553. https:\/\/doi.org\/10.1097\/00005344-199704000-00017","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10471_CR57","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/01.CIR.95.5.1214","volume":"95","author":"M Nakamura","year":"1997","unstructured":"Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K (1997) Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Circulation 95(5):1214\u20131221. https:\/\/doi.org\/10.1161\/01.CIR.95.5.1214","journal-title":"Circulation"},{"issue":"2","key":"10471_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1210\/EDRV.21.2.0396","volume":"21","author":"JP Hinson","year":"2000","unstructured":"Hinson JP, Kapas S, Smith DM (2000) Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21(2):138\u2013167. https:\/\/doi.org\/10.1210\/EDRV.21.2.0396","journal-title":"Endocr Rev"},{"key":"10471_CR59","doi-asserted-by":"publisher","unstructured":"Geven C, Kox M, Pickkers P (2018) Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis. Front Immunol 9:335741. https:\/\/doi.org\/10.3389\/FIMMU.2018.00292\/BIBTEX","DOI":"10.3389\/FIMMU.2018.00292\/BIBTEX"},{"key":"10471_CR60","doi-asserted-by":"publisher","unstructured":"Kompa AR, Lu J, Weller TJ, Kelly DJ, Krum H, Lueder TGv, et al (2018) Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. Int J Cardiol 258. https:\/\/doi.org\/10.1016\/j.ijcard.2018.01.077","DOI":"10.1016\/j.ijcard.2018.01.077"},{"key":"10471_CR61","doi-asserted-by":"publisher","unstructured":"Nord\u00e9n ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A et al (2021) Sacubitril\/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. ESC Heart Fail 8(2). https:\/\/doi.org\/10.1002\/ehf2.13177","DOI":"10.1002\/ehf2.13177"},{"key":"10471_CR62","doi-asserted-by":"publisher","unstructured":"Peng S, Lu X-f, Qi Y-d, Li J, Xu J, Yuan T-y et al (2020) LCZ696 Ameliorates oxidative stress and pressure overload-induced pathological cardiac remodeling by regulating the Sirt3\/MnSOD pathway. Oxid Med Cell Longev 2020(1). https:\/\/doi.org\/10.1155\/2020\/9815039","DOI":"10.1155\/2020\/9815039"},{"key":"10471_CR63","doi-asserted-by":"publisher","unstructured":"Yang C-C, Chen Y-T, Chen C-H, Li Y-C, Shao P-L, Huang T-H et al (2019) The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet. Biomed Pharmacother 116. https:\/\/doi.org\/10.1016\/j.biopha.2019.108954","DOI":"10.1016\/j.biopha.2019.108954"},{"issue":"1","key":"10471_CR64","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/10641963.2018.1441862","volume":"41","author":"M Imran","year":"2019","unstructured":"Imran M, Hassan MQ, Akhtar MS, Rahman O, Akhtar M, Najmi AK (2019) Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats. Clin Experiment Hypertens 41(1):5\u20135. https:\/\/doi.org\/10.1080\/10641963.2018.1441862","journal-title":"Clin Experiment Hypertens"},{"key":"10471_CR65","doi-asserted-by":"publisher","unstructured":"Liu J, Zheng X, Zhang C, Zhang C, Bu P (2021) Lcz696 alleviates myocardial fibrosis after myocardial infarction through the sFRP-1\/Wnt\/\u03b2-catenin signaling pathway. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.724147","DOI":"10.3389\/fphar.2021.724147"},{"key":"10471_CR66","doi-asserted-by":"publisher","unstructured":"Wu M, Guo Y, Wu Y, Xu K, Lin L (2021) Protective Effects of Sacubitril\/Valsartan on cardiac fibrosis and function in rats with experimental myocardial infarction involves inhibition of collagen synthesis by myocardial fibroblasts through downregulating TGF-\u03b21\/Smads pathway. Front Pharmacol 12. https:\/\/doi.org\/10.3389\/fphar.2021.696472","DOI":"10.3389\/fphar.2021.696472"},{"issue":"1","key":"10471_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1152\/JAPPLPHYSIOL.00454.2020\/ASSET\/IMAGES\/LARGE\/AJ-JAPP200087F004.JPEG","volume":"130","author":"K Bunsawat","year":"2021","unstructured":"Bunsawat K, Ratchford SM, Alpenglow JK, Park SH, Jarrett CL, Stehlik J et al (2021) Sacubitril-valsartan improves conduit vessel function and functional capacity and reduces inflammation in heart failure with reduced ejection fraction. J Appl Physiol 130(1):256\u2013268. https:\/\/doi.org\/10.1152\/JAPPLPHYSIOL.00454.2020\/ASSET\/IMAGES\/LARGE\/AJ-JAPP200087F004.JPEG","journal-title":"J Appl Physiol"},{"key":"10471_CR68","doi-asserted-by":"publisher","unstructured":"Zhang H, Liu G, Zhou W, Zhang W, Wang K, Zhang J et al (2019) Neprilysin inhibitor\u2013angiotensin II receptor blocker combination therapy (Sacubitril\/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E- deficient mice. Scientific Rep 9(1). https:\/\/doi.org\/10.1038\/s41598-019-42994-1","DOI":"10.1038\/s41598-019-42994-1"},{"key":"10471_CR69","doi-asserted-by":"publisher","unstructured":"Belali OM, Ahmed MM, Mohany M, Belali TM, Alotaibi MM, Al-Hoshani A et al (2022) LCZ696 protects against diabetic cardiomyopathy-induced myocardial inflammation, ER stress, and apoptosis through inhibiting AGEs\/NF-\u03baB and PERK\/CHOP signaling pathways. Int J Mol Sci 23(3). https:\/\/doi.org\/10.3390\/ijms23031288","DOI":"10.3390\/ijms23031288"},{"key":"10471_CR70","doi-asserted-by":"publisher","unstructured":"Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K et al (2017) LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol 108. https:\/\/doi.org\/10.1016\/j.yjmcc.2017.06.003","DOI":"10.1016\/j.yjmcc.2017.06.003"},{"key":"10471_CR71","doi-asserted-by":"publisher","unstructured":"Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 8(13). https:\/\/doi.org\/10.1161\/JAHA.119.012272","DOI":"10.1161\/JAHA.119.012272"},{"issue":"3","key":"10471_CR72","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1002\/EHF2.13285","volume":"8","author":"MG Moon","year":"2021","unstructured":"Moon MG, Hwang IC, Choi W, Cho GY, Yoon YE, Park JB et al (2021) Reverse remodelling by sacubitril\/valsartan predicts the prognosis in heart failure with reduced ejection fraction. ESC Heart Fail 8(3):2058. https:\/\/doi.org\/10.1002\/EHF2.13285","journal-title":"ESC Heart Fail"},{"key":"10471_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcha.2019.100418","volume":"3","author":"G Bayard","year":"2019","unstructured":"Bayard G, Costa AD, Pierrard R, Rom\u00e9yer-Bouchard C, Guichard JB, Isaaz K (2019) Impact of sacubitril\/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation. Int J Cardiol Heart Vasculature 3:25. https:\/\/doi.org\/10.1016\/j.ijcha.2019.100418","journal-title":"Int J Cardiol Heart Vasculature"},{"key":"10471_CR74","doi-asserted-by":"publisher","unstructured":"Castrichini M, Manca P, Nuzzi V, Barbati G, Luca AD, Korcova R et al (2020) Sacubitril\/Valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: standard and advanced echocardiographic evidences. J Clin Med 9(4). https:\/\/doi.org\/10.3390\/jcm9040906","DOI":"10.3390\/jcm9040906"},{"key":"10471_CR75","doi-asserted-by":"publisher","unstructured":"Landolfo M, Piani F, Degli Esposti D, Cosentino E, Bacchelli S, Dormi A et al (2020) Effects of sacubitril valsartan on clinical and echocardiographic parameters of outpatients with heart failure and reduced ejection fraction - PubMed. Int J Cardiol Heart Vasc 31. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100656","DOI":"10.1016\/j.ijcha.2020.100656"},{"key":"10471_CR76","doi-asserted-by":"publisher","unstructured":"Gu W, Xu C, Li Z, Li Z-Z (2021) Echocardiographic changes in elderly patients with heart failure with reduced ejection fraction after sacubitril-valsartan treatment. Cardiovasc Diagn Ther 5. https:\/\/doi.org\/10.21037\/cdt-21-355","DOI":"10.21037\/cdt-21-355"},{"issue":"2","key":"10471_CR77","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ehf2.14646","volume":"11","author":"H Liu","year":"2024","unstructured":"Liu H, Su Y, Shen J, Jiao Y, Li Y, Liu B et al (2024) Improved heart function and cardiac remodelling following sacubitril\/valsartan in acute coronary syndrome with HF. ESC Heart Fail 11(2):937\u2013949. https:\/\/doi.org\/10.1002\/ehf2.14646","journal-title":"ESC Heart Fail"},{"issue":"11","key":"10471_CR78","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/JAMA.2019.12821","volume":"322","author":"JL Januzzi","year":"2019","unstructured":"Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K et al (2019) Association of change in N-terminal Pro\u2013B-type natriuretic peptide following initiation of Sacubitril-Valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322(11):1085\u20131095. https:\/\/doi.org\/10.1001\/JAMA.2019.12821","journal-title":"JAMA"},{"issue":"2","key":"10471_CR79","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.JCHF.2018.10.014","volume":"7","author":"MA Daubert","year":"2019","unstructured":"Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S et al (2019) NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC Heart Fail 7(2):158\u2013168. https:\/\/doi.org\/10.1016\/J.JCHF.2018.10.014","journal-title":"JACC Heart Fail"},{"key":"10471_CR80","doi-asserted-by":"publisher","unstructured":"Carluccio E, Dini FL, Bitto R, Ciccarelli M, Correale M, D\u2019Agostino A et al (2022) Benefit from sacubitril\/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study. Int J Cardiol 350. https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.004","DOI":"10.1016\/j.ijcard.2022.01.004"},{"key":"10471_CR81","doi-asserted-by":"publisher","unstructured":"Zile MR, Mehra MR, Ducharme A, Sears SF, Desai AS, Maisel A et al (2022) Hemodynamically-guided management of heart\u00a0failure across the ejection\u00a0fraction spectrum: the GUIDE-HF trial. JACC: Heart Fail 10(12). https:\/\/doi.org\/10.1016\/j.jchf.2022.08.012","DOI":"10.1016\/j.jchf.2022.08.012"},{"key":"10471_CR82","doi-asserted-by":"publisher","unstructured":"Fr\u00f6hlich H, Frey N, Estler B, M\u00e4ck M, Schlegel P, Beckendorf J et al (2022) Haemodynamic effects of Sacubitril\/Valsartan initiation in outpatients with chronic heart failure. Am J Cardiovasc Drugs 22(6). https:\/\/doi.org\/10.1007\/s40256-022-00549-2","DOI":"10.1007\/s40256-022-00549-2"},{"key":"10471_CR83","doi-asserted-by":"publisher","unstructured":"Zhang J, Du L, Qin X, Guo X (2022) Effect of Sacubitril\/Valsartan on the right ventricular function and pulmonary hypertension in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of observational studies - PubMed. J Am Heart Assoc. 11(9). https:\/\/doi.org\/10.1161\/JAHA.121.024449","DOI":"10.1161\/JAHA.121.024449"},{"key":"10471_CR84","doi-asserted-by":"publisher","unstructured":"Gentile P, Cantone R, Perna E, Ammirati E, Varrenti M, D\u2019Angelo L et al (2022) Haemodynamic effects of sacubitril\/valsartan in advanced heart failure. ESC Heart Fail 9(2). https:\/\/doi.org\/10.1002\/ehf2.13755","DOI":"10.1002\/ehf2.13755"},{"issue":"5","key":"10471_CR85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/FJC.0000000000001477","volume":"82","author":"J Brockm\u00f6ller","year":"2023","unstructured":"Brockm\u00f6ller J, Ivanoski S, Hundack L, Blohm J-H, Januszewski M, Remppis BA et al (2023) Clinical and hemodynamic improvement in pulmonary hypertension after switching to Sacubitril\/Valsartan in patients with heart failure with preserved ejection fraction. J Cardiovasc Pharmacol 82(5):5\u20135. https:\/\/doi.org\/10.1097\/FJC.0000000000001477","journal-title":"J Cardiovasc Pharmacol"},{"key":"10471_CR86","doi-asserted-by":"publisher","unstructured":"Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K et al (2016) Influence of Ejection fraction on outcomes and efficacy of Sacubitril\/Valsartan (LCZ696) in heart failure with reduced ejection fraction. Circulation: Heart Fail 9(3). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002744","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744"},{"issue":"22","key":"10471_CR87","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/J.JACC.2016.09.931","volume":"68","author":"MR Zile","year":"2016","unstructured":"Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL et al (2016) Prognostic implications of changes in N-terminal Pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 68(22):2425\u20132436. https:\/\/doi.org\/10.1016\/J.JACC.2016.09.931","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10471_CR88","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748\/-\/DC1","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013748\/-\/DC1","journal-title":"Circulation"},{"issue":"9851","key":"10471_CR89","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"SD Solomon","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (London, England) 380(9851):1387\u20131395. https:\/\/doi.org\/10.1016\/S0140-6736(12)61227-6","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10471_CR90","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427","volume":"7","author":"PS Jhund","year":"2014","unstructured":"Jhund PS, Claggett BL, Voors AA, Zile MR, Packer M, Pieske BM et al (2014) Elevation in high-sensitivity troponin t in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Circulation: Heart Fail 7(6):953\u20139. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.114.001427","journal-title":"Circulation: Heart Fail"},{"issue":"5","key":"10471_CR91","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/J.JCHF.2020.03.002","volume":"8","author":"JW Cunningham","year":"2020","unstructured":"Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M et al (2020) Effects of Sacubitril\/Valsartan on N-terminal Pro-B-type natriuretic peptide in heart\u00a0failure with preserved ejection fraction. JACC: Heart Fail 8(5):372\u201381. https:\/\/doi.org\/10.1016\/J.JCHF.2020.03.002","journal-title":"JACC: Heart Fail"},{"issue":"5","key":"10471_CR92","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","volume":"141","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K et al (2020) Sacubitril\/Valsartan across the spectrum of ejection fraction in heart failure. Circulation 141(5):352\u2013361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044586","journal-title":"Circulation"},{"key":"10471_CR93","doi-asserted-by":"publisher","unstructured":"McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J et al (2020) Effects of Sacubitril-Valsartan versus Valsartan in women compared with men with heart failure and preserved ejection fraction. Circulation 338\u201351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044491","DOI":"10.1161\/CIRCULATIONAHA.119.044491"},{"key":"10471_CR94","unstructured":"American College of Cardiology (2015) FDA approves new heart failure drug. https:\/\/www.acc.org\/latest-incardiology\/articles\/2015\/07\/08\/10\/00\/fda-approves-new-heart-failure-drug. Accessed 9 July 2024"},{"issue":"1","key":"10471_CR95","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Boehm M et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131. https:\/\/doi.org\/10.1002\/ejhf.2333","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10471_CR96","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","volume":"139","author":"DA Morrow","year":"2019","unstructured":"Morrow DA, Velazquez EJ, Devore AD, Desai AS, Duffy CI, Ambrosy AP et al (2019) Clinical outcomes in patients with acute decompensated heart failure randomly assigned to Sacubitril\/Valsartan or Enalapril in the PIONEER-HF trial. Circulation 139(19):2285\u20132288. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039331","journal-title":"Circulation"},{"issue":"3","key":"10471_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/J.JACC.2019.11.003","volume":"75","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S et al (2020) Prior heart failure hospitalization, clinical outcomes, and response to Sacubitril\/Valsartan compared with Valsartan in HFpEF. J Am Coll Cardiol 75(3):245\u2013254. https:\/\/doi.org\/10.1016\/J.JACC.2019.11.003","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10471_CR98","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/EJHF.1498","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z et al (2019) Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 21(8):998\u20131007. https:\/\/doi.org\/10.1002\/EJHF.1498","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10471_CR99","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/EJHF.1465","volume":"21","author":"R Wachter","year":"2019","unstructured":"Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienger R et al (2019) Real-world treatment patterns of sacubitril\/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail 21(5):588\u2013597. https:\/\/doi.org\/10.1002\/EJHF.1465","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10471_CR100","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCULATIONAHA.121.057429","volume":"145","author":"MA Pfeffer","year":"2022","unstructured":"Pfeffer MA, Claggett B, Lewis EF, Granger CB, K\u00f8ber L, Maggioni AP et al (2022) Impact of Sacubitril\/Valsartan versus Ramipril on total heart failure events in the PARADISE-MI Trial. Circulation 145(1):87\u201389. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057429","journal-title":"Circulation"},{"issue":"6","key":"10471_CR101","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1002\/ehf2.14159","volume":"9","author":"A Bellis","year":"2022","unstructured":"Bellis A, Mauro C, Barbato E, Trimarco B, Morisco C (2022) The PARADISE-MI trial: a new opportunity to improve the left ventricular remodelling in reperfused STEMI. ESC Heart Fail 9(6):3698\u20133701. https:\/\/doi.org\/10.1002\/ehf2.14159","journal-title":"ESC Heart Fail"},{"issue":"6","key":"10471_CR102","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1002\/EHF2.13677","volume":"8","author":"B Xiong","year":"2021","unstructured":"Xiong B, Nie D, Qian J, Yao Y, Yang G, Rong S et al (2021) The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail 8(6):4852\u20134862. https:\/\/doi.org\/10.1002\/EHF2.13677","journal-title":"ESC Heart Fail"},{"key":"10471_CR103","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/J.AMJCARD.2020.12.037","volume":"143","author":"A Rezq","year":"2021","unstructured":"Rezq A, Saad M, El Nozahi M (2021) Comparison of the efficacy and safety of Sacubitril\/Valsartan versus Ramipril in patients with ST-segment elevation myocardial infarction. Am J Cardiol 143:7\u201313. https:\/\/doi.org\/10.1016\/J.AMJCARD.2020.12.037","journal-title":"Am J Cardiol"},{"key":"10471_CR104","doi-asserted-by":"publisher","unstructured":"Shah AM, Claggett B, Prasad N, Li G, Volquez M, Jering K et al (2022) Impact of Sacubitril\/Valsartan compared to Ramipril on cardiac structure and function following acute myocardial infarction: the PARADISE-MI echocardiographic sub-study. Circulation 146(14). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059210","DOI":"10.1161\/CIRCULATIONAHA.122.059210"},{"issue":"11","key":"10471_CR105","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","volume":"139","author":"DH Kang","year":"2019","unstructured":"Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS et al (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: PRIME study. Circulation 139(11):1354\u20131365. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037077","journal-title":"Circulation"},{"key":"10471_CR106","doi-asserted-by":"publisher","unstructured":"Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J et al (2019) Effect of sacubitril-valsartan vs enalapril on aortic stiffness in heart failure and reduced ejection fraction. JAMA 322(11). https:\/\/doi.org\/10.1001\/jama.2019.12843","DOI":"10.1001\/jama.2019.12843"},{"issue":"9","key":"10471_CR107","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/EJHF.548","volume":"18","author":"M Senni","year":"2016","unstructured":"Senni M, McMurray JJV, Wachter R, McIntyre HF, Reyes A, Majercak I et al (2016) Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 18(9):1193\u20131202. https:\/\/doi.org\/10.1002\/EJHF.548","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10471_CR108","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMOA1908655\/SUPPL_FILE\/NEJMOA1908655_DATA-SHARING.PDF","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620. https:\/\/doi.org\/10.1056\/NEJMOA1908655\/SUPPL_FILE\/NEJMOA1908655_DATA-SHARING.PDF","journal-title":"N Engl J Med"},{"issue":"9","key":"10471_CR109","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/EJHF.2271","volume":"23","author":"G Savarese","year":"2021","unstructured":"Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR et al (2021) Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail 23(9):1499\u20131511. https:\/\/doi.org\/10.1002\/EJHF.2271","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10471_CR110","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/EJHF.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K et al (2016) Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail 18(10):1228. https:\/\/doi.org\/10.1002\/EJHF.580","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10471_CR111","doi-asserted-by":"publisher","first-page":"e12435","DOI":"10.1111\/1755-5922.12435","volume":"36","author":"P Martens","year":"2018","unstructured":"Martens P, Beli\u00ebn H, Dupont M, Vandervoort P, Mullens W (2018) The reverse remodeling response to sacubitril\/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Therap. 36(4):e12435-e. https:\/\/doi.org\/10.1111\/1755-5922.12435","journal-title":"Cardiovasc Therap."},{"issue":"1","key":"10471_CR112","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ehf2.14163","volume":"10","author":"T Hamada","year":"2023","unstructured":"Hamada T, Kubo T, Kawai K, Nakaoka Y, Yabe T, Furuno T et al (2023) Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction. ESC Heart Fail 10(1):223\u2013233. https:\/\/doi.org\/10.1002\/ehf2.14163","journal-title":"ESC Heart Fail"},{"issue":"12","key":"10471_CR113","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/J.JCHF.2021.06.018","volume":"9","author":"AP Carnicelli","year":"2021","unstructured":"Carnicelli AP, Li Z, Greiner MA, Lippmann SJ, Greene SJ, Mentz RJ et al (2021) Sacubitril\/valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction. JACC Heart Fail 9(12):876\u2013886. https:\/\/doi.org\/10.1016\/J.JCHF.2021.06.018","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10471_CR114","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ehf2.14600","volume":"11","author":"M Iacoviello","year":"2024","unstructured":"Iacoviello M, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M et al (2024) Pharmacoutilization and adherence to sacubitril\/valsartan in real world: the REAL.IT study in HFrEF. ESC Heart Fail 11(1):456\u201365. https:\/\/doi.org\/10.1002\/ehf2.14600","journal-title":"ESC Heart Fail"},{"key":"10471_CR115","doi-asserted-by":"publisher","unstructured":"Avaldi VM, Lenzi J, Urbinati S, Molinazzi D, Descovich C, Campagna A et al (2017) Effect of cardiologist care on 6-month outcomes in patients discharged with heart failure: results from an observational study based on administrative data. BMJ open 7(11). https:\/\/doi.org\/10.1136\/BMJOPEN-2017-018243","DOI":"10.1136\/BMJOPEN-2017-018243"},{"issue":"2","key":"10471_CR116","doi-asserted-by":"publisher","first-page":"e001294","DOI":"10.1136\/OPENHRT-2020-001294","volume":"7","author":"EE Nielsen","year":"2020","unstructured":"Nielsen EE, Feinberg JB, Bu FL, Hecht Olsen M, Raymond I, Steensgaard-Hansen F et al (2020) Beneficial and harmful effects of sacubitril\/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart 7(2):e001294-e. https:\/\/doi.org\/10.1136\/OPENHRT-2020-001294","journal-title":"Open Heart"},{"key":"10471_CR117","doi-asserted-by":"publisher","unstructured":"Yu W, Zhang H, Shen W, Luo F, Yang S, Gan L et al (2022) Efficacy and safety of sacubitril\/valsartan on heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Front Cardiovasc Med 9. https:\/\/doi.org\/10.3389\/FCVM.2022.897423\/FULL","DOI":"10.3389\/FCVM.2022.897423\/FULL"},{"key":"10471_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2024.02.035","author":"A Fo\u00e0","year":"2024","unstructured":"Fo\u00e0 A, Vaduganathan M, Claggett BL, Pabon MA, Lu H, Pfeffer MA et al (2024) Sacubitril\/valsartan-related hypotension in patients with heart failure and preserved or mildly reduced ejection fraction. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/J.JACC.2024.02.035","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10471_CR119","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/ehf2.13891","volume":"9","author":"P Tolomeo","year":"2022","unstructured":"Tolomeo P, Zucchetti O, D\u2019Aniello E, Punzo N, Marchini F, Di Ienno L et al (2022) Left ventricular output indices and sacubitril\/valsartan titration: role of stroke volume index. ESC Heart Failure 9(3):2037\u20132043. https:\/\/doi.org\/10.1002\/ehf2.13891","journal-title":"ESC Heart Failure"},{"key":"10471_CR120","doi-asserted-by":"publisher","unstructured":"Bruno RM, Taddei S (2017) Sacubitril\/valsartan and low blood pressure in heart failure with reduced ejection fraction. European Heart J 38(15). https:\/\/doi.org\/10.1093\/eurheartj\/ehx014","DOI":"10.1093\/eurheartj\/ehx014"},{"key":"10471_CR121","doi-asserted-by":"publisher","unstructured":"B\u00f6hm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP et al (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF - PubMed. European Heart J 38(15). https:\/\/doi.org\/10.1093\/eurheartj\/ehw570","DOI":"10.1093\/eurheartj\/ehw570"},{"key":"10471_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2024.09.002","author":"H Tsutsui","year":"2024","unstructured":"Tsutsui H, Momomura S-i, Saito Y, Ito H, Yamamoto K, Sakata Y et al (2024) Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril\/valsartan or enalapril: results from the PARALLEL-HF study. J Cardiol. https:\/\/doi.org\/10.1016\/j.jjcc.2024.09.002","journal-title":"J Cardiol"},{"issue":"11","key":"10471_CR123","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/EJHF.1987","volume":"22","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Mogensen UM, Jhund PS, Desai AS, Rouleau JL, Zile MR et al (2020) Serum potassium in the PARADIGM-HF trial. European J Heart Fail 22(11):2056. https:\/\/doi.org\/10.1002\/EJHF.1987","journal-title":"European J Heart Fail"},{"key":"10471_CR124","doi-asserted-by":"publisher","unstructured":"Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K et al (2017) Reduced risk of hyperkalemia using sacubitril\/valsartan vs enalapril. JAMA Cardiol 2(1). https:\/\/doi.org\/10.1001\/jamacardio.2016.4733","DOI":"10.1001\/jamacardio.2016.4733"},{"key":"10471_CR125","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","volume":"331","author":"C Proudfoot","year":"2021","unstructured":"Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S et al (2021) Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review. Int J Cardiol 331:164\u2013171. https:\/\/doi.org\/10.1016\/j.ijcard.2021.01.061","journal-title":"Int J Cardiol"},{"issue":"6","key":"10471_CR126","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/J.JCHF.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP et al (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 6(6):489\u2013498. https:\/\/doi.org\/10.1016\/J.JCHF.2018.02.004","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10471_CR127","doi-asserted-by":"publisher","first-page":"782","DOI":"10.11909\/J.ISSN.1671-5411.2020.12.002","volume":"17","author":"Y Chen","year":"2020","unstructured":"Chen Y, Guo LY, Zhao LF, Ma YH, Zhu XL, Xu Y et al (2020) Can sacubitril\/valsartan become the promising drug to delay the progression of chronic kidney disease? J Geriatric Cardiol: JGC 17(12):782. https:\/\/doi.org\/10.11909\/J.ISSN.1671-5411.2020.12.002","journal-title":"J Geriatric Cardiol: JGC"},{"key":"10471_CR128","doi-asserted-by":"publisher","unstructured":"Masarone D, Melillo E, Errigo V, Valente F, Pacileo G (2021) Clinical relevance of transient worsening renal function after initiation of sacubitril\/valsartan. Curr Med Res Opinion 37(1). https:\/\/doi.org\/10.1080\/03007995.2020.1853509","DOI":"10.1080\/03007995.2020.1853509"},{"key":"10471_CR129","doi-asserted-by":"publisher","unstructured":"Clase CM, Barzilay J, Gao P, Smyth A, Schmieder RE, Tobe S et al (2017) Acute change in glomerular filtration rate with\u00a0inhibition of the renin-angiotensin system\u00a0does not\u00a0predict subsequent renal and\u00a0cardiovascular\u00a0outcomes. Kidney Int. 91(3). https:\/\/doi.org\/10.1016\/j.kint.2016.09.038","DOI":"10.1016\/j.kint.2016.09.038"},{"issue":"5","key":"10471_CR130","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/EJHF.232","volume":"17","author":"AA Voors","year":"2015","unstructured":"Voors AA, Gori M, Liu LCY, Claggett B, Zile MR, Pieske B et al (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17(5):510\u2013517. https:\/\/doi.org\/10.1002\/EJHF.232","journal-title":"Eur J Heart Fail"},{"issue":"13","key":"10471_CR131","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","volume":"142","author":"FR Mc Causland","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M et al (2020) angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation 142(13):1236\u20131245. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047643","journal-title":"Circulation"},{"issue":"5","key":"10471_CR132","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1002\/ehf2.13963","volume":"9","author":"A Arcudi","year":"2022","unstructured":"Arcudi A, Di Francesco M, Rodolico D, D\u2019Amario D (2022) Angiotensin receptor-neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: a primetime. ESC Heart Fail 9(5):3639\u20133642. https:\/\/doi.org\/10.1002\/ehf2.13963","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10471_CR133","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/ehf2.14466","volume":"10","author":"M Tajstra","year":"2023","unstructured":"Tajstra M, Dyrbu\u015b M, Rutkowski T, Sk\u0142adowski K, Sosnowska-Pasiarska B, G\u00f3\u017ad\u017a S et al (2023) Sacubitril\/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial. ESC Heart Fail 10(5):3174\u20133183. https:\/\/doi.org\/10.1002\/ehf2.14466","journal-title":"ESC Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10471-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10471-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10471-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T08:01:47Z","timestamp":1738828907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10471-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":133,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["10471"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10471-1","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"28 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jan Biegus has received honoraria from Bayer, Boehringer Ingelheim, and AstraZeneca for lectures and from Alleviant Medical and WhiteSwell for participation in clinical trial advisory boards. Jan Biegus is a member of the Editorial Board of Heart Failure Reviews.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}